Buy-rated reports

511 tickers rated Buy
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Tencent Music Entertainment Group
TME·Communication Services
A ★★★★Buy
Current$9.13
Target$12.00
Return+31.4%
Nov 20, 2026

Tencent Music combines a cash-generative subscription franchise, expanding premium memberships, and attractive valuation with meaningful upside potential, although Ximalaya integration costs and Chinese platform competition remain key risks.

Score
83
CGI Inc.
GIB·Technology
A ★★★★Buy
Current$81.79
Target$91.52
Return+11.9%
Nov 14, 2026

CGI combines durable managed-services contracts, strong free cash flow, and disciplined buybacks with an attractive valuation, although slow organic growth and AI-driven pressure on IT service pricing remain significant challenges.

Score
83
H&R Block, Inc.
HRB·Consumer Discretionary
A ★★★★Buy
Current$50.98
Target$61.40
Return+20.4%
Nov 12, 2026

H&R Block combines a durable tax-preparation franchise, strong cash generation, and aggressive share repurchases with an attractive earnings valuation, although digital competition and tax simplification threaten long-term pricing power.

Score
83
Qualys, Inc.
QLYS·Technology
A ★★★★Buy
Current$182.69
Target$200.79
Return+9.9%
Nov 12, 2026

Qualys combines a profitable, cash-generative cybersecurity subscription franchise with expanding risk-management opportunities, although competition from larger security platforms and moderate revenue growth constrain its upside.

Score
83
Skyward Specialty Insurance Group, Inc.
SKWD·Financials
A ★★★★Buy
Current$60.35
Target$69.13
Return+14.5%
Nov 8, 2026

Skyward Specialty offers profitable niche insurance growth and attractive capital compounding at a reasonable valuation, although Apollo integration, insurance pricing cycles and unexpected claims could weaken future returns.

Score
83
The Cigna Group
CI·Healthcare
A ★★★★Buy
Current$293.59
Target$350.60
Return+19.4%
Nov 8, 2026

Cigna combines substantial cash generation, growing specialty-care profits, and a modest earnings valuation, offering attractive long-term upside if pharmacy-benefit margin pressure and regulatory changes remain manageable.

Score
83
EOG Resources, Inc.
EOG·Energy
A ★★★★Buy
Current$147.13
Target$162.10
Return+10.2%
Nov 8, 2026

EOG combines low-cost oil and gas production, strong free cash flow, and disciplined shareholder returns at an attractive valuation, although commodity-price volatility and resource depletion constrain earnings predictability.

Score
83
Gold Fields Limited
GFI·Materials
A ★★★★Buy
Current$39.17
Target$46.98
Return+19.9%
Nov 8, 2026

Gold Fields combines strong gold-price-driven cash generation, a growing production base, and attractive valuation multiples, but commodity cyclicality, mining inflation, and development spending constrain sustainable upside.

Score
83
Cirrus Logic, Inc.
CRUS·Technology
A ★★★★Buy
Current$113.58
Target$131.20
Return+15.5%
Nov 7, 2026

Cirrus Logic combines high-return semiconductor intellectual property, substantial free cash flow, and attractive valuation with HPMS growth opportunities, but extreme customer concentration makes future design wins and pricing pressure critical risks.

Score
83
Insulet Corporation
PODD·Healthcare
A ★★★★Buy
Current$146.51
Target$170.94
Return+16.7%
Nov 7, 2026

Insulet combines recurring Omnipod revenue, strong international growth, and improving profitability with a sharply compressed valuation, although intensifying insulin pump competition and weaker cash conversion threaten future returns.

Score
83
Grand Canyon Education, Inc.
LOPE·Consumer Staples
A ★★★★Buy
Current$117.69
Target$151.20
Return+28.5%
Nov 7, 2026

Grand Canyon Education combines exceptional cash generation, high capital returns, and an attractive valuation, but its dependence on Grand Canyon University and changing service-fee economics create substantial concentration risk.

Score
83
CF Industries Holdings, Inc.
CF·Materials
A ★★★★Buy
Current$119.39
Target$124.96
Return+4.7%
Nov 7, 2026

CF Industries combines low-cost nitrogen production, strong cash generation, and shareholder-friendly capital allocation with an attractive valuation, although fertilizer-price cyclicality and major project execution risks limit earnings predictability.

Score
83